In this commentary, we synthesize current evidence and expert perspectives, drawing on presentations from the 42nd International Symposium on Diabetes and Nutrition by the Diabetes and Nutrition Study Group, to provide practical guidance on optimizing the use of GLP-1 therapies in obesity and diabetes management. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.